Sight Sciences (NASDAQ:SGHT) Insider Jeremy Hayden Sells 12,733 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy Hayden sold 12,733 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $5.51, for a total value of $70,158.83. Following the sale, the insider owned 357,037 shares in the company, valued at approximately $1,967,273.87. This trade represents a 3.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Sight Sciences Price Performance

Sight Sciences stock opened at $5.43 on Tuesday. The stock’s 50 day moving average is $4.95 and its 200 day moving average is $5.31. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.86 and a quick ratio of 5.48. The firm has a market cap of $295.23 million, a P/E ratio of -7.65 and a beta of 2.38. Sight Sciences, Inc. has a one year low of $3.11 and a one year high of $9.24.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.05). The business had revenue of $19.70 million for the quarter, compared to the consensus estimate of $18.46 million. Sight Sciences had a negative return on equity of 52.34% and a negative net margin of 46.83%. As a group, research analysts expect that Sight Sciences, Inc. will post -0.6 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on SGHT shares. Weiss Ratings lowered shares of Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Citigroup raised their target price on Sight Sciences from $4.35 to $5.15 and gave the stock a “neutral” rating in a research note on Thursday, May 28th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $8.14.

More Sight Sciences News

Here are the key news stories impacting Sight Sciences this week:

• Negative Sentiment: CEO Paul Badawi sold 28,684 shares, trimming his stake by about 0.47%, in the largest disclosed insider transaction. Sight Sciences (NASDAQ:SGHT) CEO Paul Badawi Sells 28,684 Shares of Stock
• Negative Sentiment: CFO James Rodberg sold 6,902 shares, reducing his ownership by nearly 3%, adding to the selling pressure from senior leadership. Sight Sciences (NASDAQ:SGHT) CFO Sells 6,902 Shares
• Negative Sentiment: CTO David Badawi sold 7,418 shares, while insider Jeremy B. Hayden sold 12,733 shares, reinforcing the pattern of insider reductions. Insider Selling: Sight Sciences (NASDAQ:SGHT) CTO Sells $40,873.18 in Stock Sight Sciences (NASDAQ:SGHT) Insider Sells 12,733 Shares of Stock
• Negative Sentiment: EVP Brenton Taylor also sold shares, continuing the broad pattern of insider selling across multiple executives. Sight Sciences (NASDAQ:SGHT) EVP Sells $15,333.18 in Stock

Institutional Investors Weigh In On Sight Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its position in Sight Sciences by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock valued at $26,000 after purchasing an additional 3,785 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after purchasing an additional 2,875 shares during the period. Diversified Trust Co purchased a new stake in Sight Sciences in the first quarter worth approximately $51,000. XTX Topco Ltd bought a new stake in Sight Sciences in the 2nd quarter worth approximately $67,000. Finally, O Shaughnessy Asset Management LLC purchased a new stake in Sight Sciences during the 4th quarter valued at $81,000. 55.51% of the stock is owned by hedge funds and other institutional investors.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.